drugset / Trial / NCT00423969

Galantamine Augmentation of Escitalopram for Treatment of Depression

NCT00423969

Phase 4 Terminated 20 enrolled Indiana University
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to investigate whether the addition of galantamine to a commonly used antidepressant, escitalopram (Lexapro), will be useful in the treatment of memory and other thinking problems that are frequently seen in depression. At present, galantamine is approved for use in the treatment of Alzheimer's disease or dementia, but not for use for the treatment of depression in younger patients. Possible genetic effects of depressed individuals will also be studied. This study is involved in collecting blood from patients with depression. DNA, the genetic material in our cells, will be obtained from these blood samples. The DNA will be studied to determine the contribution of different genes to the development of depression. These blood samples are extremely useful to researchers who are trying to determine the genetic risk factors that may lead to depression.

Timeline

Start
2003-11
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule
Background Escitalopram Small molecule

Indications